DE69529912T2 - Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor - Google Patents

Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor

Info

Publication number
DE69529912T2
DE69529912T2 DE69529912T DE69529912T DE69529912T2 DE 69529912 T2 DE69529912 T2 DE 69529912T2 DE 69529912 T DE69529912 T DE 69529912T DE 69529912 T DE69529912 T DE 69529912T DE 69529912 T2 DE69529912 T2 DE 69529912T2
Authority
DE
Germany
Prior art keywords
slpi
methods
inhibitor
tryptase
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69529912T
Other languages
English (en)
Other versions
DE69529912D1 (de
Inventor
K Muller
Elise Brownell
A Delaria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of DE69529912D1 publication Critical patent/DE69529912D1/de
Publication of DE69529912T2 publication Critical patent/DE69529912T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69529912T 1994-09-12 1995-09-11 Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor Expired - Fee Related DE69529912T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/304,051 US5633227A (en) 1994-09-12 1994-09-12 Secretory leukocyte protease inhibitor as an inhibitor of tryptase
PCT/US1995/011445 WO1996008275A1 (en) 1994-09-12 1995-09-11 Secretory leukocyte protease inhibitor as an inhibitor of tryptase

Publications (2)

Publication Number Publication Date
DE69529912D1 DE69529912D1 (de) 2003-04-17
DE69529912T2 true DE69529912T2 (de) 2003-11-06

Family

ID=23174847

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69529912T Expired - Fee Related DE69529912T2 (de) 1994-09-12 1995-09-11 Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor

Country Status (9)

Country Link
US (1) US5633227A (de)
EP (1) EP0787016B1 (de)
JP (1) JPH10505833A (de)
AT (1) ATE234117T1 (de)
CA (1) CA2199746A1 (de)
DE (1) DE69529912T2 (de)
ES (1) ES2194057T3 (de)
MX (1) MX9701869A (de)
WO (1) WO1996008275A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507165A (pt) * 1994-03-23 1997-09-09 Tokyo Tanase Company Limited Inibidor da triptase clara agente terapêutico ou profilático para doenças virais processo terapêutico para doenças virais e uso da antileucoprotease
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
DK1588716T3 (da) 1998-08-06 2011-05-23 Mountain View Pharmaceuticals Peg-uratoxidase-konjugater og anvendelse deraf
CA2383486A1 (en) * 1999-02-01 2000-08-03 Darren Lezdey Treatment of bladder and gastrointestinal mastocytosis
GB9916913D0 (en) * 1999-07-19 1999-09-22 Natural Enviromental Research Inhibitor proteins
WO2001009165A2 (en) * 1999-07-29 2001-02-08 The Johns Hopkins University ACTIVATION OF PEPTIDE PRODRUGS BY hK2
JP4610832B2 (ja) * 1999-10-26 2011-01-12 株式会社 ジャパン・ティッシュ・エンジニアリング 創収縮抑制薬剤
CN101011584A (zh) * 1999-12-28 2007-08-08 诺瓦提斯公司 获得持续的转基因表达的方法
AU2001231030A1 (en) * 2000-01-20 2001-07-31 Amgen Inc Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
AU6346901A (en) * 2000-05-25 2001-12-03 Curagen Corp Method of detecting inflammatory lung disorders
ATE510214T1 (de) * 2000-11-30 2011-06-15 Crawford Healthcare Holdings Ltd Krankheitsdiagnose
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
CA2430973A1 (en) * 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
DE10101793A1 (de) * 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
EP1613653A1 (de) * 2003-04-08 2006-01-11 Genova Ltd. Sezernierte polypeptide zur diagnose von kardiovaskulären krankheiten
MX2007001638A (es) * 2004-08-11 2009-02-12 Trubion Pharmaceuticals Inc Proteinas de fusion del dominio de unión.
SI3321359T1 (sl) 2005-04-11 2021-07-30 Horizon Pharma Rheumatology Llc Variantne oblike urat oksidaze in uporaba le-teh
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
BRPI0612942A2 (pt) 2005-04-11 2012-10-09 Savient Pharmaceuticals Inc forma variante de oxidase de urato e uso do mesmo
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
MX2008009105A (es) * 2006-01-12 2008-09-26 Janssen Pharmaceutica Nv Procesamiento del inhibidor de proteasa de leucocitos de secrecion (slpi) por quimasa.
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
WO2009045508A1 (en) * 2007-10-02 2009-04-09 Research Foundation Of City University Of New York Novel protein transduction domains derived from secretory leukocyte protease inhibitor
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3175699D1 (en) * 1980-04-02 1987-01-22 Fisons Plc Salts and aqueous solutions of 6-methylamino-4-oxo-10-propyl-4h-pyrano(3,2-g)-quinoline-2,8-di-carboxylic acid and pharmaceutical compositions containing such salts and solutions
US5089634A (en) * 1984-08-20 1992-02-18 Georgia Tech Research Corporation Isocoumarins with cationic substituents
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
WO1986003497A1 (en) * 1984-12-06 1986-06-19 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
US4760130A (en) * 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
DE3600571A1 (de) * 1986-01-10 1987-08-06 Gruenenthal Gmbh Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel
US5190917A (en) * 1986-12-24 1993-03-02 John Lezdey Treatment of psoriasis
US5290762A (en) * 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
CA1340877C (en) * 1987-12-28 2000-01-18 Takashi Sugiyama Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
KR920700287A (ko) * 1989-02-22 1992-02-19 사와무라 하루오 신규의 프로테아제 억제물질 및 그것의 제조방법
US5215965A (en) * 1990-10-02 1993-06-01 John Lezdey Treatment of inflammation
EP0503203A1 (de) * 1991-03-15 1992-09-16 Merrell Dow Pharmaceuticals Inc. Neue Thrombin-Inhibitoren

Also Published As

Publication number Publication date
EP0787016A1 (de) 1997-08-06
WO1996008275A1 (en) 1996-03-21
EP0787016B1 (de) 2003-03-12
ES2194057T3 (es) 2003-11-16
EP0787016A4 (de) 1998-02-04
US5633227A (en) 1997-05-27
MX9701869A (es) 1997-06-28
DE69529912D1 (de) 2003-04-17
JPH10505833A (ja) 1998-06-09
CA2199746A1 (en) 1996-03-21
ATE234117T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
DE69529912D1 (de) Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor
PT739355E (pt) Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos
ATE520411T1 (de) Behandlung und prävention von lungenerkrankungen
PL319782A1 (en) Inhibitors of serinic proteases and anticoagulative protecins extracted from nematodes
ATE249421T1 (de) Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DE60023266D1 (de) Serinprotease-inhibitoren
DE69735545D1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
DK1144365T3 (da) Inhibitorer af alfa4beta1-medieret celleadhæsion
DE69333639D1 (en) Trypsininhibitoren
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE208793T1 (de) Thrombin-inhibitoren
DE69431603T2 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
MY130725A (en) Composition and method for treating allergic diseases
ATE377586T1 (de) Tripeptidylpeptidaseinhibitoren
DE50202331D1 (de) Verwendung eines phosphatadsorbers gegen gefässerkrankungen
DE60107516D1 (de) Verwendung von Pregabalin zur Asthma Behandlung
AR020741A1 (es) Composicion y metodo para tratar enfermedades alergicas
PT1032415E (pt) Prevencao e/ou tratamento de condicoes alergicas
ATE213644T1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
ATE526954T1 (de) Atomoxetin zur behandlung von allergischer rhinitis und asthma
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DE60105425D1 (de) Menschlicher site-1 protease-spezifischer promotor
ECSP993167A (es) Composicion y metodo para tratar enfermedades alergicas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee